mRNA-In® Neuro, is a new, mRNA transfection reagent specifically designed and optimized for high efficiency mRNA delivery with exceptionally low cytotoxicity in neurons.
Unlike other competitor reagents, mRNA-In® Neuro requires very low amounts of RNA to achieve maximum delivery while maintaining optimal cell viability.
mRNA-In® Neuro Transfection Reagent is a next generation low-toxicity mRNA delivery system for achieving maximum transfection efficiency in hard to transfection neurons.
It is well suited for various neurobiology applications, including neurotoxicity and neurite outgrowth development. Data here shows mRNA-In® typically achieves 70% or greater transfection
efficiency in primary neurons. With mRNA-In® Neuro, mRNA expression levels using can be adjusted by changing the amount of mRNA transfection. Moreover, mRNA-In® Neuro requires very
low amounts of mRNA (up to 5-fold less that competitor reagents) to achieve maximum transfection efficiency in neurons, significantly minimizing unintended off-target immune activation and toxicity effects.
- Maximum efficiency with low amounts of mRNA - Maximally effective with very low amounts of mRNA, significantly minimizing
potential adverse off-target cytotoxic effects and supporting maximum cell health and viability.
- High expression, low toxicity - Achieves high mRNA efficiency and protein expression in hard to transfect neurons while maintaining optimal cell health for uncompromised post-transfection assay results.
- Versatile performance - Highly efficient and reproducible transfection performance across a wide range of primary cells.
- Rapid expression and Easy to Use - Use without the risk of integration with the cellular host genome and observe more rapid expression as early as 4 hours post-transfection.
- Well suited for various applications - Shown to be effective across a range of applications, including neurotoxicity and neurite development.
Low Amounts of mRNA Achieve Maximum RNA Delivery in Neurons:
Figure 1. Superior mRNA Transfection efficiency in Primary Neurons. Primary rat cortical neurons cultured in 24-well plates were transfected with mRNA-In® Neuro
Transfection Reagent and incubated overnight in complete culture media. Maximum transfection efficiency was maintained with reducing amounts of mRNA, from 500ng (high) to 125ng (low) amounts of mRNA. The above images were
taken 48-hours post-transfection. In contrast to DNA transfection, neurons transfected with mRNA-In® Neuro showed uniform GFP expression from high (500ng) to very low (125ng) amounts of mRNA.
Figure 2. mRNA-In® Neuro Outperforms Competitor Reagents. mRNA-In® Neuro Transfection Reagent was compared to MessengerMax for transfecting neurons. Primary cortical neurons in
culture for 6 days were transfected with 500ng and 250ng amounts of modified mRNA and 2μl mRNA-In® Neuro or MessengerMax in 24-well plates. Cells were incubated overnight in complete culture media and observed 24hr and 48hrs (not shown)
post-transfection. Above images show significantly higher transfection efficiency and GFP expression in healthy neurons post transfection
Messenger RNA (mRNA) delivery has become a widely used non-viral gene delivery alternative due to its many advantages, including no risk of integration into the host genome which can lead to insertional mutagenesis and activation of
oncogenes, and as shown here the ability to achieve very high transfection efficiencies, nearing that of viral delivery methods. In contrast with DNA transfection, mRNA delivery does not enter the nucleus, rather only cytosolic delivery
is required, resulting in more a rapid expression. mRNA-In® Neuro, is specifically designed and optimized for high efficiency mRNA delivery with exceptionally low cytotoxicity in neurons. Unlike all other competitor reagent mRNA-In®
Neuro requires very low amounts of RNA to achieve maximum delivery while maintaining optimal cell viability.
MessengerMax is a Life Technologies, Inc registered trademark